Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2021 06:30 ET | Source: Veru Inc.

Veru Reports Record Fiscal 2021 Full-Year Financial Results

--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of...
November 18, 2021 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
November 18, 2021 08:00 ET | Source: Veru Inc.

Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500

-- Veru is a Late-Stage Clinical Development Biopharmaceutical Company Developing Drugs for the Treatment of Breast Cancer, Prostate Cancer, and COVID-19, Large Premium Global Markets– -- 212%...
November 08, 2021 08:30 ET | Source: Veru Inc.

Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,...
October 13, 2021 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed,...
September 20, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
September 09, 2021 08:30 ET | Source: Veru Inc.

Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
September 08, 2021 08:30 ET | Source: Veru Inc.

Veru to Present at Three Upcoming Healthcare Investment Conferences

MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
August 12, 2021 06:30 ET | Source: Veru Inc.

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter

--Q3 FY21 Net Revenues Increase 71% to $18M and Gross Profit Increases 113% to $14M, Achieving New Historical Highs— --Nine-Month FY21 Year to Date Net Revenues Increased 48% to $46M, also a Record...
July 29, 2021 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th

MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...